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Is there still a need for albumin infusions to treat patients with
liver disease?
The course of patients with cirrhosis is frequently compli-
cated by derangement of body fluid homeostasis which
results in accumulation of large amounts of extracellular
fluid in the peritoneal cavity and interstitial tissue.1 Investi-
gations performed in the 1940s proposed that the
formation of ascites and oedema was related to an
imbalance in Starling’s equilibrium in splanchnic and sys-
temic capillaries caused by increased hydrostatic pressure
due to portal hypertension and reduced oncotic pressure
because of the low serum albumin levels characteristic of
cirrhosis, which would favour the passage of fluid from the
intravascular compartment to the interstitial tissue.2–4 Later
studies showed that patients with cirrhosis and ascites have
marked circulatory dysfunction, characterised mainly by
low systemic vascular resistance and arterial pressure,
abnormal distribution of blood volume, with reduced cen-
tral blood volume, and marked stimulation of vasoconstric-
tor and antinatriuretic systems (that is, the renin-
angiotensin-aldosterone system and sympathetic nervous
system).5 6 In some patients this circulatory dysfunction is
so intense that renal perfusion is greatly reduced leading to
severe impairment of renal function, a condition known as
hepatorenal syndrome.7 Considering all of these factors it
is not surprising that albumin infusions have been used for
many years in the management of patients with cirrhosis
and ascites in an attempt to reduce the formation of ascites
and/or improve circulatory and renal function.8 In the cur-
rent decade the use of albumin in cirrhosis has regained
attention because of the demonstration that patients with
large ascites can be treated safely with large volume
paracentesis associated with albumin infusions.9 While
some of these indications for albumin infusions are
supported by the results of randomised studies, others are
based on clinical experience and have not been proved in
prospective investigations. Therefore, the use of albumin
infusions in patients with cirrhosis is controversial.
Recently, this debate has been fostered by the high cost and
limited availability of albumin and the results of a
meta-analysis showing that albumin administration may
increase mortality in critically ill patients.10
This article will review the use of albumin infusions in the
management of patients with cirrhosis and ascites on the
basis of the current knowledge of the pathogenesis of ascites
and renal dysfunction in cirrhosis. The information given
does not apply to the clinical situation of patients with
cirrhosis and dehydration because of excessive loss of extra-
cellular fluid (that is, intense vomiting, diarrhoea, or
overdiuresis) or gastrointestinal haemorrhage who should
be treated with intravenous fluids or plasma expanders as
in patients without liver disease under similar clinical
conditions.
Pathogenesis of ascites and renal dysfunction in
cirrhosis: role of circulatory dysfunction
Apart from sodium retention, the key factor for the devel-
opment of ascites, patients with cirrhosis may also show
impaired ability to eliminate water which may lead to dilu-
tional hyponatraemia and renal vasoconstriction that, if
severe, may result in hepatorenal syndrome.1 7 Investiga-
tions carried out over the past two decades have provided
convincing evidence indicating that these abnormalities of
renal function and the formation of ascites in cirrhosis are
related to a marked disturbance in circulatory function.11–13
This circulatory dysfunction consists of reduced total sys-
temic vascular resistance, arterial hypotension, and high
cardiac output. Total blood volume is not reduced, as pro-
posed initially by the classical underfilling theory of ascites
formation, but increased compared with that of healthy
subjects. The reduction in total systemic vascular resist-
ance is mainly due to marked arterial vasodilatation in the
splanchnic circulation because the resistance to blood flow
in non-splanchnic vascular beds (that is, upper and lower
limbs, kidneys, and brain) is normal or even increased.11–13
The exact mechanism(s) leading to this vasodilatation is
not completely understood but may involve increased
synthesis/activity of vasodilator factors, including nitric
oxide and vasodilator peptides.14 15 The marked splanchnic
arterial vasodilatation would be responsible not only for the
reduction in total systemic vascular resistance but also for
an abnormal distribution of blood volume with reduction
of eVective arterial blood volume (that is, the blood volume
in the heart, lungs, and central arterial tree that is sensed by
arterial receptors) and subsequent baroreceptor mediated
activation of vasoconstrictor and antinatriuretic factors.13 It
is currently believed that this reduction in eVective arterial
blood volume is fundamental to the development of
sodium retention in cirrhosis. The predominant accumula-
tion of the retained fluid in the peritoneal cavity as ascites
would be a consequence of a high filtration rate in the
splanchnic capillaries resulting from both a backward and
forward increase in hydrostatic pressure due to portal
hypertension and splanchnic arterial vasodilatation, re-
spectively, and an increased capillary filtration
coeYcient.16 17 Dilutional hyponatraemia and hepatorenal
syndrome are also pathogenetically related to circulatory
dysfunction and depend, among other factors, on non-
osmotic hypersecretion of antidiuretic hormone and the
action of vasoconstrictor factors on the renal circulation,
respectively.1 Renal dysfunction in cirrhosis is of great
clinical importance because its intensity correlates with
prognosis.1
EVects of albumin infusions in the management of
renal dysfunction in patients with cirrhosis and
ascites
Albumin infusions have been used in the management of
patients with cirrhosis and ascites with two main objectives:
(1) to reduce the formation of ascites and oedema by
increasing microvascular oncotic pressure; and (2) to
improve circulatory and renal function by expanding total
blood volume.8 The first of these two eVects was
investigated in studies carried out between the 1940s and
1960s. Most showed that despite a pronounced increase in
serum albumin levels and normalisation of oncotic
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pressure, the rate of ascites formation did not decrease
consistently, even when albumin was given for prolonged
periods.18–21 Apart from proving the lack of eYcacy of albu-
min for this purpose, the results of these studies were of
pathophysiological relevance because they demonstrated
that the decrease in oncotic pressure plays no significant
role in the pathogenesis of ascites formation in cirrhosis.
Administration of plasma expanders has been used
extensively in clinical practice to improve renal function in
patients with cirrhosis and ascites despite the lack of avail-
able evidence supporting such an indication. Albumin has
been the plasma expander most commonly used because of
its greater oncotic potency and longer plasma half life
compared with artificial plasma expanders.22 Administra-
tion of albumin to patients with cirrhosis and ascites causes
an increase in total blood volume followed by a moderate
reduction, but not normalisation, of the activity of
vasoconstrictor and antinatriuretic systems. These circula-
tory changes are associated with favourable eVects on renal
function, especially on renal plasma flow and glomerular
filtration rate. However, these renal eVects are modest and
limited only to patients with normal or slightly impaired
renal function, whereas patients with severe renal dysfunc-
tion do not show any beneficial response.20 23–25 Suppression
of the activity of antinatriuretic systems, particularly the
renin-angiotensin-aldosterone system, probably accounts
for an increase in the natriuretic response to diuretics
observed in patients treated with repeated albumin
infusions.26 However, this beneficial eVect is of small clini-
cal relevance to justify the use of such therapy in patients
with cirrhosis and ascites.
The reason why albumin infusions fail to consistently
improve circulatory and renal function in patients with
cirrhosis and ascites is not completely known. It may be
related to the short lived eVect of albumin in expanding total
plasma volume because the transvascular escape rate of
albumin (that is, the rate of albumin that escapes from the
intravascular compartment to the interstitial tissue) is
increased in patients with cirrhosis compared with that of
healthy subjects.27 However, this explanation seems unlikely
because neither circulatory function nor renal function
improve after repeated albumin infusions.23 The most likely
explanation is that albumin cannot increase eVective arterial
blood volume eYciently despite the increase in total blood
volume because of the extreme vasodilatation present in the
splanchnic circulation. The results of a recent study showing
that in patients with advanced cirrhosis acute volume expan-
sion is associated with a marked increase in non-central
blood volume but no significant changes in central blood
volume is in keeping with such a suggestion.28 Moreover, this
explanation is also supported by the observation that both
circulatory and renal function improve markedly after the
combined administration of albumin and ornipressin, a
derivative of arginine vasopressin (the antidiuretic hormone)
with marked vasoconstrictor activity in the splanchnic
circulation.29
EVects of albumin infusions in the prevention of
renal dysfunction in patients with cirrhosis and
ascites
The circulatory dysfunction causing impairment in eVec-
tive arterial blood volume and subsequent renal dysfunc-
tion in cirrhosis with ascites is not a fixed, unalterable dis-
order. Rather its intensity may increase as a consequence of
the evolution of the disease or by intercurrent processes.
To date, two diVerent situations that may further impair
circulatory function in cirrhotic patients with ascites have
been identified: large volume paracentesis and spontane-
ous bacterial peritonitis. Removal of large amounts of
ascitic fluid is characterised by early favourable haemody-
namic eVects with suppression of vasoconstrictor and anti-
natriuretic factors and increased plasma natriuretic peptide
levels. However, this is followed by a second phase charac-
terised by marked activation of vasoconstrictor and
antinatriuretic factors in the absence of changes in plasma
volume, consistent with impairment of eVective arterial
blood volume.9 This post-paracentesis circulatory dysfunc-
tion occurs in most patients treated with large taps, is not
spontaneously reversible, and is associated with impair-
ment of renal function and decreased survival.9 30 31 The
occurrence of such circulatory dysfunction and the subse-
quent development of dilutional hyponatraemia and renal
failure after large volume paracentesis can be prevented
successfully by administration of albumin (8 g/l of ascites
removed).9 30 31
A second condition that may impair circulatory function
in patients with cirrhosis and ascites is spontaneous bacte-
rial peritonitis, a disorder characterised by spontaneous
infection of ascites due in most cases to the passage of bac-
teria from the intestinal flora to the ascitic fluid.32 Patients
with spontaneous bacterial peritonitis frequently develop
changes in circulatory function consistent with impairment
of eVective arterial blood volume, which is associated with
renal failure in approximately one-third of patients. This
impairment in renal function is probably related to the high
level of cytokines and vasodilator factors in plasma and
ascitic fluid, occurs despite the resolution of the infection
by antibiotic therapy, and is associated with an impaired
prognosis.33 34 The eYcacy of albumin in the prevention of
circulatory and renal dysfunction in patients with cirrhosis
and spontaneous bacterial peritonitis has been assessed
recently in a prospective, randomised study in which
patients received either conventional antibiotic therapy
alone or in association with albumin infusions (1.5 g/kg
body weight at the time of diagnosis of the infection and 1
g/kg two days later).35 The results of this study showed that
the occurrence of circulatory dysfunction, as assessed by
changes in the activity of the renin-angiotensin-aldosterone
system, and renal failure were much lower in patients
treated with albumin infusions than in those who received
antibiotic therapy alone, despite a similar rate of infection
resolution. Most importantly, administration of albumin
infusions was associated with a longer survival. These
results, therefore, support the use of albumin infusions as a
regular treatment for spontaneous bacterial peritonitis in
patients with cirrhosis.
Role of albumin infusions in the treatment of
hepatorenal syndrome
Hepatorenal syndrome represents the extreme expression
of circulatory dysfunction in cirrhosis with ascites.1 7 12 13
This condition is characterised by very low arterial
pressure and total systemic vascular resistance, marked
overactivity of vasoconstrictor factors (renin-angiotensin
and sympathetic nervous systems, antidiuretic hormone,
and endothelin), and marked arterial vasoconstriction in
the kidney and other vascular territories (muscle, skin, and
brain). Plasma volume expansion with albumin, as well as
other procedures that cause expansion of total blood
volume (infusion of ascitic fluid or peritoneovenous shunt-
ing), have traditionally been used in the management of
patients with hepatorenal syndrome with little success.1 36
Although these therapeutic manoeuvres result in transient
suppression of renal vasoconstrictor factors, which indi-
cates amelioration of circulatory function, the increase in
renal perfusion and glomerular filtration rate is only
marginal. Similar findings have been reported with the use
of vasoconstrictor drugs (ornipressin or midodrine).1 36–38
However, two recent studies have shown that when
cirrhotic patients with ascites and hepatorenal syndrome
Is there still a need for albumin infusions in liver disease? 589
are treated for several days or weeks with a combination of
vasoconstrictors and plasma volume expansion with albu-
min infusions, a marked improvement in circulatory and
renal function occurs in most cases with normalisation of
plasma levels of vasoconstrictor factors and serum
creatinine.29 39 Interestingly, hepatorenal syndrome may
not recur after treatment withdrawal and the survival of
patients may be prolonged suYciently in some cases to
reach liver transplantation.
Summary and conclusions
There is a strong body of evidence indicating that renal
functional abnormalities and ascites formation in cirrhosis
are the final consequence of circulatory dysfunction char-
acterised by marked splanchnic arterial vasodilatation
causing a reduction in eVective arterial blood volume and
homeostatic activation of vasoconstrictor and antinatriu-
retic mechanisms. In contrast, there is no evidence to sup-
port a role for reduced vascular oncotic pressure due to
hypoalbuminaemia in the pathogenesis of ascites.
Although albumin infusions have been used extensively in
clinical practice in patients with cirrhosis to improve renal
function and facilitate elimination of ascites, the beneficial
eVects of albumin are very modest and limited only to
patients with slightly impaired renal function who respond to
conventional therapy. Therefore, the available clinical
evidence does not support the use of albumin infusions for
such indications. In contrast, albumin infusions are very
eVective in preventing the deterioration in renal function
associated with large volume paracentesis or spontaneous
bacterial peritonitis, conditions that are known to cause
impairment of circulatory function in patients with cirrhosis
and ascites. Moreover, albumin infusions improve survival in
patients with spontaneous bacterial peritonitis. Taken
together, these data suggest that albumin can prevent renal
impairment by maintaining eVective arterial blood volume
in situations characterised by acute deterioration in circula-
tory function. In contrast, when circulatory dysfunction is
already established, albumin alone is not eVective in improv-
ing renal function. The recent demonstration that concomi-
tant administration of albumin and vasoconstrictor drugs
acting preferentially in the splanchnic circulation normalises
almost completely circulatory function and improves renal
function in patients with cirrhosis and hepatorenal syndrome
opens a new indication for albumin infusions in patients with
liver disease.
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